ライフサイエンスコーパス: GRP

1 GRP antagonists should be considered for further develop

2 GRP blockade diminished serine phosphorylation of GRPR w

3 GRP blockade is a novel radiation fibrosis mitigating ag

4 GRP blockade with 77427 treatment diminished CD68(+), GR

5 GRP had the same effects as bombesin, whereas neither NM

6 GRP is a tissue equivalent to the mouse node, in which c

7 GRP may be a target for novel therapies to reduce the ri

8 GRP receptor expression was increased in the spinal cord

9 GRP stimulated contractions acutely when added to freshl

10 GRP-R expression of 50 clinical BC specimens and the cor

11 GRP-R expression was also analyzed in 9 BC cell lines ap

12 GRP-R knockdown also up-regulated the expression of tumo

13 GRP-R tumor expression was positively (P = 0.026, chi(2)

14 GRPs also extended survival and disease duration, attenu

15 GRPs survived in diseased tissue, differentiated efficie

16 The SARNC ([(N4)Gly(18)]GRP(18-27)) analogs (SARNC2 dAla(24), SARNC3 dAla(24)/Nl

17 Compound 1a (GRP-74915) was selected for development based on activit

18 (Bmax) of 414 fmol/10(6) cells (2.5 x 10(5) GRP-R/cell).

19 n 1 (XBP1) and glucose-regulated protein 78 (GRP 78), and nuclear translocation of activating transcr

20 Glucose-regulated protein-78 (GRP-78) is an endoplasmic reticulum chaperone protein th

21 binding to the glucose-regulated protein-78 (GRP-78) localized on the plasma membrane of preodontobla

22 r colony formation, which was inhibited by a GRP-blocking antibody.

23 depletion or neutralization of TNF abrogates GRP-induced neutrophil recruitment to the peritoneum.

24 this article we demonstrate that abrogating GRP/GRPR signaling specifically down-regulates HP1(Hsbet

25 f a known smooth muscle stimulatory agonist, GRP.

26 Although GRP is known to participate in meal-stimulated acid secr

27 pes of CSPG printed on cover glass, although GRPs were still responsive to the remaining repulsive si

28 ows: SAP, 2.177; SWAP, 1.96; FDP, 1.277; and GRP, 1.04.

29 ies of experiments performed in GRP::cre and GRP::eGFP transgenic male mice.

30 P, 4.85 dB; SWAP, 9.03 dB; FDP, 4.29 dB; and GRP, 1.36 dB.

31 confirm spatial co-localization of DMP1 and GRP-78 in the preodontoblasts of a developing mouse mola

32 endently attenuates both beta-endorphin- and GRP-elicited robust scratching without affecting pain pr

33 ed trained observers for SAP, SWAP, FDP, and GRP.

34 Our findings demonstrate that GRP and GRP-R have important oncogenic properties beyond their e

35 Coactivation of 5-HT1A and GRP receptors (GRPR) greatly potentiates subthreshold, G

36 sory neurons for non-histaminergic itch, and GRP sensory neurons are dedicated to itch transmission.

37 Thus, we propose that NMB and GRP may transmit discrete itch information and NMBR neur

38 nistration, beta-endorphin (10-100 nmol) and GRP (1-10 nmol) dose-dependently elicit the same degree

39 ited by mu-opioid peptide (MOP) receptor and GRP receptor (BB2) antagonists, respectively.

40 g effects by beta-endorphin-MOP receptor and GRP-BB2 receptor systems and itch-inhibiting effects by

41 GRP antiserum in tissues from wild-type and GRP mutant mice indicates that the antiserum is only sel

42 ivocal evidence that AuNP-BBN constructs are GRP-receptor-specific showing accumulation with high sel

43 Furthermore, silencing GRP-R as well as GRP in BE(2)-C cells suppressed anchorage-independent gr

44 test whether AP5 would be able to attenuate GRP-induced shifts 15 min following microinjection of GR

45 tivation with decoy oligonucleotides blocked GRP-induced phase shifts of PER2::luciferase rhythms in

46 High-affinity receptors for BN/GRP were found on tumors.

47 Western blot analaysis, and receptors for BN/GRP were investigated by radioligand-binding studies.

48 Our findings demonstrate the efficacy of BN/GRP antagonist RC-3940-II for the treatment of NSCLC.

49 The effect of the administration of BN/GRP antagonist RC-3940-II on the growth of H460 and A549

50 ght contribute to the antitumor action of BN/GRP antagonists.

51 We evaluated whether antagonists of BN/GRP can suppress the growth of human non-SCLC (NSCLC) xe

52 Antagonists of BN/GRP have been shown to inhibit these cancers.

53 Bombesin/GRP can induce features of BPD, including interstitial f

54 bolism, were also significantly decreased by GRP-R silencing.

55 mis of the skin is exclusively innervated by GRP fibers, whose activation via optogeneics and chemoge

56 rvival and metastasis, was down-regulated by GRP-R silencing.

57 ade with 77427 treatment diminished CD68(+), GRP(+), and pSmad2/3(+) cells.

58 In conclusion, GRP antagonists reduce volume of human prostatic cells a

59 In contrast, GRP/GRPR can be aberrantly expressed in colon cancer whe

60 ffect in promoting the migration of cultured GRPs.

61 In addition, RHBDF1 gene silencing disrupts GRP-stimulated secretion of EGFR ligand TGF-alpha, but n

62 xenografts in SCID mice, with [(111)In-DOTA]GRP(17-27) exhibiting the most favorable pharmacokinetic

63 The shorter chain [(111)In-DOTA]GRP(17/18-27) analogs showed higher metabolic stability

64 essing Foxj1 is sufficient to induce ectopic GRP-like cilia formation in frog embryos.

65 unable to demonstrate a role for endogenous GRP in meal-stimulated gastrin secretion in humans.

66 Enhanced GRP expression and sustained ERK phosphorylation were ob

67 acrophages, T cells, and neutrophils express GRP receptor (GRPR).

68 ficial dorsal horn interneurons that express GRP and that likely target GRPR-expressing interneurons.

69 nd BC cell lines (6/9) were found to express GRP-R.

70 RP produced aggressive tumors, which express GRP, prostate-specific antigen, and nuclear-localized AR

71 Strong extracellular GRP immunostaining was observed in lung at 6 hours post-

72 that the descending 5-HT system facilitates GRP-GRPR signaling via 5-HT1A to augment itch-specific o

73 However, mRNA for GRP is widely distributed among excitatory interneurons

74 tes that the antiserum is only selective for GRP at high dilutions.

75 (either directly purified or generated from GRP cells).

76 de HSV-based neuronal tracing initiated from GRP neurons revealed ascending polysynaptic projections

77 A gastrin-releasing peptide (GRP)/GRP receptor-mediated autocrine pathway was previously d

78 mmunoreactive terminals, altered dorsal horn GRP immunoreactivity.

79 data confirm a critical role of dorsal horn GRP neurons in spinal itch transmission but do not suppo

80 However, GRP, which is known to be limited by retinal sampling ra

81 otected N(4)-chelator to neuromedin C (human GRP(18-27)), which, after (99m)Tc-labeling, afforded [(9

82 study has demonstrated the efficacy of human GRP-based radiopeptides to target GRPR-positive lesions

83 perspectives of radioligands based on human GRP sequences in the detection and therapy of GRPR-expre

84 Thus, human GRP-based radioligands, such as [(99m)Tc]Demomedin C, ca

85 recently expanded this approach toward human GRP(18-27) sequences and introduced (99m)Tc-demomedin C,

86 chains of CSPG with chondroitinase improved GRP migration on stripes of CSPG printed on cover glass,

87 2 and the posterior localization of cilia in GRP cells, demonstrating its role in PCP.

88 key steps in mediating downstream events in GRP resetting of SCN neurons.

89 tion in a series of experiments performed in GRP::cre and GRP::eGFP transgenic male mice.

90 howing accumulation with high selectivity in GRP-receptor-rich pancreatic acne in normal mice and als

91 th antisense oligodeoxynucleotides inhibited GRP-induced increases in spike frequency.

92 first-in-class direct-acting RABV inhibitor, GRP-60367, with a specificity index (SI) of >100,000.

93 mall population of dorsal horn interneurons (GRP neurons).

94 we demonstrate that the receptor for DMP1 is GRP-78.

95 CaP cells and the resultant cell line, LNCaP-GRP, exhibited androgen-independent growth with enhanced

96 ally implanted in castrated nude mice, LNCaP-GRP produced aggressive tumors, which express GRP, prost

97 romatin immunoprecipitation studies of LNCaP-GRP clones suggest that GRP activates and recruits AR to

98 and imaging potential of (177)Lu-AMBA in low GRP-R models of prostate cancer and determine how reduce

99 We determined urine GRP levels and lung GRP immunostaining in mice 0 to 24 after post-thoracic R

100 amount of intraspecific polymorphism in male GRPs may be a consequence of the relative efficiency of

101 abeled truncated analogs of the human 27-mer GRP after conjugation of 1,4,7,10-tetraazacyclododecane-

102 In both models, GRP blockade abrogated AHR and bronchoalveolar lavage (B

103 BALB/c mice were given small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11,

104 Moreover, GRP-R deficiency significantly delayed tumor growth and

105 d fear acquisition and expression in a mouse GRP.

106 learning and highlight the utility of mouse GRPs for the identification of genes underlying complex

107 that peripheral nerve injury induced de novo GRP expression in DRG neurons points to a novel contribu

108 NRP/GRP with and without NBQX produced a significant recover

109 Nine days post-injury, NRP/GRP were delivered into the lesion site.

110 Similarly, NBQX&NRP/GRP induced more spouting, regeneration or sparing of de

111 s receiving the combined treatment (NBQX&NRP/GRP) had voided volumes/micturition resembling that of n

112 mbined treatments was similar to that of NRP/GRP alone with decreased sprouting of primary afferents

113 In conclusion, transplants of NRP/GRP combined with NBQX promote recovery of micturition f

114 euronal and glial restricted precursors (NRP/GRP) derived from the embryonic spinal cord of alkaline

115 Controls received NRP/GRP grafts only or no treatment (OP-Controls).

116 e of the lesion to a greater extent than NRP/GRP alone or OP-Controls.

117 nt of urodynamic parameters, compared to NRP/GRP alone or OP-Controls.

118 Spinally restricted ablation of GRP neurons reduced itch-related behaviors to different

119 on of AP5 15 min after the administration of GRP were not different from those that received microinj

120 ed significantly with an excessive amount of GRP antagonists.

121 have demonstrated that potent antagonists of GRP inhibit growth of experimental human tumors includin

122 this study was to explore the application of GRP-R radioligands for imaging and therapy of BC by intr

123 ow that Pk3 is enriched at the basal body of GRP cells but is recruited by Vangl2 to anterior cell bo

124 hese findings suggest a signaling cascade of GRP-Src-PI3-K-PDK1-TACE-amphiregulin-EGFR with multiple

125 Mice given one dose of GRP monoclonal antibody 2A11 24 hours post-RT had signif

126 Here, we evaluated the effects of GRP antagonist RC-3940-II on viability and cell volume o

127 All effects of GRP were abrogated in GRPR-null mice.

128 GRPR appears to mediate all effects of GRP, but only part of the bombesin effect on alveolariza

129 uman neuroblastomas; however, the effects of GRP/GRP-R on tumorigenesis and metastasis in vivo are no

130 Differential expression of GRP-78 mRNA and protein was observed upon in vitro diffe

131 umor cell line has an elevated expression of GRP-Rs (2.5 x 10(5)/cell), whereas LNCaP--a prostate can

132 paradigm shift in the biological function of GRP-78.

133 e selective uptake of this new generation of GRP-receptor-specific AuNP-BBN peptide analogs has demon

134 sions in vivo and has revealed the impact of GRP chain length on key biological parameters of resulti

135 APK and AKT, accompanied by an inhibition of GRP-induced survival, proliferation, and invasion of the

136 Here we demonstrate that i.p. injection of GRP attracts neutrophils in 4 h, and attraction is block

137 The intrathecal injection of GRP led to intense scratching, an effect largely reduced

138 er cell lines expressing different levels of GRP and integrin receptors, and their intracellular loca

139 We have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nano

140 demonstrate the cell surface localization of GRP-78 and provide evidence that it functions as a recep

141 t from those that received microinjection of GRP and vehicle.

142 ed shifts 15 min following microinjection of GRP.

143 In vivo microinjections of GRP to the SCN regions of Per1::green fluorescent protei

144 Conversely, overexpression of GRP-R in less aggressive SK-N-SH neuroblastoma cells res

145 Up-regulation of GRP mRNA by stretch was confirmed in a separate series o

146 Here, we tested the putative role of GRP as an intra-SCN light signal at the behavioral and c

147 To determine the role of GRP in sensory neurons, we generated a floxed Grp mouse

148 In the present study we explored the role of GRP-78 in mineralized matrix formation.

149 mechanism(s) mediating the oncogenic role of GRP/GRP-R and demonstrates a novel role for AKT2 in neur

150 tetraacetic acid (DOTA) at the N-terminus of GRP(13/14/17/18-27) fragments.

151 ngly inhibited the adhesion and migration of GRPs, an effect that could be modulated by the adhesion

152 ssibility of producing a migratory stream of GRPs via directional cues to create a supportive pathway

153 -demomedin C, our first radiotracer based on GRP(18-27), showing favorable biologic characteristics d

154 transmission-to reach oxytocin receptors on GRP neurons and facilitate male sexual function.

155 c signal, but that this dependency ends once GRP-dependent signaling is complete.

156 small molecule GRP blocking agent 77427, or GRP blocking antibody 2A11, before exposure to ozone or

157 nt study tests whether exogenous bombesin or GRP given perinatally alters alveolar development in new

158 Inhibition of either BRAF or GRP signaling attenuated itch sensation in chronic itch

159 ow that itch deficits in mice lacking NMB or GRP are non-redundant and Nmb/Grp double KO (DKO) mice d

160 tocrine neuropeptide model by overexpressing GRP in LNCaP cells and the resultant cell line, LNCaP-GR

161 duces itch and attenuates inflammatory pain, GRP only elicits itch without affecting pain.

162 Mouse genetic reference panels (GRPs) provide one approach for identifying genetic sourc

163 an inhibition of gastrin-releasing peptide (GRP) -induced phosphorylation of EGFR and EGFR-dependent

164 tes targeting the gastrin-releasing peptide (GRP) and integrin receptors is reported.

165 The gastrin-releasing peptide (GRP) and its receptor (GRPR) are important components of

166 ations induced by gastrin-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.

167 genes, including gastrin-releasing peptide (GRP) and MAS-related GPCR member A3 (MRGPRA3), in nocice

168 these processes: gastrin-releasing peptide (GRP) and the small conductance, calcium-activated potass

169 rons that express gastrin-releasing peptide (GRP) are part of the circuit for pruritogen-evoked itch.

170 Bombesin (BN) or gastrin-releasing peptide (GRP) can stimulate the growth of neoplasms such as breas

171 polypeptide (VIP)/gastrin-releasing peptide (GRP) cells located ventrally in the SCN receive retinal

172 Gastrin-releasing peptide (GRP) functions as a neurotransmitter for non-histaminerg

173 ated peptides and gastrin-releasing peptide (GRP) in awake, behaving monkeys.

174 microinjection of gastrin-releasing peptide (GRP) into the third ventricle or near the suprachiasmati

175 Gastrin-releasing peptide (GRP) is a neuropeptide that acts through G protein coupl

176 Gastrin-releasing peptide (GRP) is a spinal itch transmitter expressed by a small p

177 es suggested that gastrin-releasing peptide (GRP) is an itch-specific neurotransmitter.

178 Gastrin-releasing peptide (GRP) is localized to the SCN ventral retinorecipient zon

179 Gastrin-releasing peptide (GRP) is synthesized by pulmonary neuroendocrine cells in

180 normally express gastrin-releasing peptide (GRP) or its receptor (GRPR).

181 Gastrin-releasing peptide (GRP) receptors (GRPr) are frequently overexpressed in hu

182 h affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostat

183 iously shown that gastrin-releasing peptide (GRP) stimulates neuroblastoma growth, and that its cell

184 The gastrin-releasing peptide (GRP) system in the lumbosacral spinal cord is an importa

185 e determined that gastrin-releasing peptide (GRP) was elevated within days after birth in newborns ex

186 Two probes for gastrin-releasing peptide (GRP), a known stimulatory agonist of smooth muscle, were

187 (CART), galanin, gastrin-releasing peptide (GRP), neuropeptide Y (NPY), nitric oxide synthase (NOS),

188 Gastrin-releasing peptide (GRP), secreted by pulmonary neuroendocrine cells, mediat

189 al peptide (VIP), gastrin-releasing peptide (GRP), substance P, and calcitonin gene-related peptide (

190 Exemplified by gastrin-releasing peptide (GRP), these neuropeptides transmit their signals through

191 r in facilitating gastrin-releasing peptide (GRP)-dependent scratching behavior.

192 was also found on gastrin-releasing peptide (GRP)-positive neurons (pruriceptive fibers), and AYP-ind

193 pressin (AVP) and gastrin-releasing peptide (GRP).

194 neurotransmitter, gastrin-releasing peptide (GRP).

195 A gastrin-releasing peptide (GRP)/GRP receptor-mediated autocrine pathway was previou

196 Gastrin releasing-peptide (GRP) is a potent growth factor in many malignancies.

197 mmalian bombesin (gastrin-releasing peptide [GRP]) drop postnatally, but these levels are elevated in

198 erning on the Xenopus gastrocoel roof plate (GRP) and zebrafish Kupffer's vesicle are severely shorte

199 leftward flow at the gastrocoel roof plate (GRP), and aberrant expression of both Coco and Pitx2c we

200 a Prickle, in Xenopus gastrocoel roof plate (GRP).

201 rogenitor cells, glial-restricted precursor (GRP) cells and oligodendrocyte/type-2 astrocyte progenit

202 cursors, called glial-restricted precursors (GRPs).

203 Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further ev

204 Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 ampli

205 splantation of glial-restricted progenitors (GRPs) is a promising strategy for generating a supportiv

206 rough direct inhibitory effects on prostatic GRP receptors.

207 gression requires glucose regulated protein (GRP) 78 for cancer cell survival and proliferation, as w

208 Glucose Regulated Protein (GRP) 94 and GRP78 are critical molecular chaperones and

209 ticulum chaperone glucose-regulated protein (GRP) 94.

210 haperones such as glucose-regulated protein (GRP) and protein-disulphide isomerase (PDI), which assis

211 and identified it as a glycine-rich protein (GRP).

212 d divergence of gamete recognition proteins (GRPs) can result in reproductive isolation.

213 Two new classes of radiolabeled GRP receptor antagonists are studied and compared with t

214 of oxidized proteins with Girard P reagent (GRP; 1-(2-hydrazino-2-oxoethyl)pyridinium chloride), (2)

215 -coupled gastrin-releasing peptide receptor (GRP-R) and is currently in phase I clinical trials.

216 ting the gastrin-releasing peptide receptor (GRP-R) might offer a specific method for imaging and the

217 in-releasing peptide (GRP) and its receptor, GRP-R, in neuroblastoma.

218 growth, and that its cell surface receptor, GRP-R, is overexpressed in advanced-stage human neurobla

219 ificantly elevated between 24 hours post-RT; GRP-blocking monoclonal antibody 2A11, given minutes pos

220 beling of mAbs was developed on a Scintomics GRP 2V module and comprised the following steps: reagent

221 apitulated by chemogenetic inhibition of SCN GRP neurons.

222 Activation of SCN GRP/GRPR neurons evoked scratching behavior.

223 Here, we show that SEG/GRP neurons express oxytocin receptors and are activated

224 YP-induced itch was reduced by the selective GRP receptor antagonist RC-3095.

225 Seven GRP-derivatized peptides were found to be selected from

226 peripheral nerve injury induced significant GRP expression in a heterogeneous population of DRG neur

227 Furthermore, silencing GRP-R as well as GRP in BE(2)-C cells suppressed anchora

228 ors (GRPR) greatly potentiates subthreshold, GRP-induced Ca(2+) transients, and action potential firi

229 to produce a migratory stream of supportive GRPs.

230 Targeting GRP-R-expressing BC tumors using GRP-R radioligands is p

231 , and immunohistochemistry, we conclude that GRP is expressed abundantly in spinal cord, but not in D

232 We also confirmed that GRP-R is upstream of AKT2 and in turn, regulated N-myc e

233 Considering that GRP blockade abrogates pulmonary inflammation and fibros

234 Our findings demonstrate that GRP and GRP-R have important oncogenic properties beyond

235 These data demonstrate that GRP-GRPR signaling is necessary and sufficient for trans

236 nd optogenetic experiments demonstrated that GRP neurons receive direct input from MrgprA3-positive p

237 the RABV glycoprotein (G) demonstrated that GRP-60367 inhibits entry of a subset of RABV strains.

238 We provide evidence that GRP-78 can bind to DMP1 and type I collagen independent

239 We found that GRP neurons form a rather homogeneous population of cent

240 In the present study, we found that GRP-R knockdown in the aggressive cell line BE(2)-C indu

241 To test the hypothesis that GRP mediates asthma, we used two murine models: ozone ex

242 Altogether, these results indicate that GRP communicates phase resetting signals within the SCN

243 These data indicate that GRP is a neuropeptide in sensory neurons for non-histami

244 of calcium and phosphate ions indicated that GRP-78 can induce the formation of calcium phosphate pol

245 Our data are the first to show that GRP blockade decreases inflammatory and fibrotic respons

246 Our data show that GRP directly activates small-size capsaicin-sensitive DR

247 g and retrograde tracing studies showed that GRP-expressing neurons of the superficial dorsal horn ar

248 ion studies of LNCaP-GRP clones suggest that GRP activates and recruits AR to the cognate promoter in

249 airway inflammation in mice, suggesting that GRP blockade is promising as a broad-spectrum therapeuti

250 An interesting observation was that GRP-78 was identified in the secretome of these cells an

251 The GRP-eGFP cells are separate from several other neurochem

252 amma (PKCgamma), but that none coexpress the GRP receptor (GRPR).

253 177Lu-AMBA has a high affinity for the GRP-R (Kd, 1.02 nmol/L), with a maximum binding capacity

254 nged incubation of stretched explants in the GRP antagonists PD-176252 or RC-3095 (65 and 24 h, respe

255 tricted to a discrete subset of cells in the GRP::eGFP mouse, some of which express the neuromedin re

256 y during time, the absorbance at 420 nm, the GRP (grape reaction products) and hydroxycinnamic acids

257 Western blot demonstrated expression of the GRP receptor in 9 out of a further 9 cases.

258 n experiments confirm the involvement of the GRP receptor in both the phototherapeutic activity as we

259 ogen-independent growth and migration of the GRP-expressing cell lines, and blocks the nuclear transl

260 D and MCF7 xenografts after injection of the GRP-R antagonist (111)In-JMV4168.

261 situation, and little definitive work on the GRP-R status of primary prostate tumors and metastases e

262 xicity of (177)Lu-AMBA was determined on the GRP-R-expressing BC cell line T47D.

263 therapy (PDT) of cancers overexpressing the GRP receptor.

264 tumorigenesis, indicating that targeting the GRP/GRP-R/AKT2 axis may be important for developing nove

265 We found that the GRP receptor antagonist RC-3059 and the SK2 specific blo

266 These findings demonstrate that the GRP-eGFP cells constitute a discrete population of excit

267 studied by in vitro autoradiography with the GRP-R agonist (111)In-AMBA.

268 Therefore, GRP-R may be an ideal therapeutic target for the treatme

269 uences of mammary-targeted knockout of these GRPs.

270 This GRP, as well as its minimal peptide epitope Crip21, serv

271 Thus, GRP mediates AHR and airway inflammation in mice, sugges

272 (177)Lu-AMBA binds to GRP-R in these cell lines with high affinity (K(d) of LN

273 Binding of DMP1 to GRP-78 receptor was determined to be specific and satura

274 mbesin family of peptides closely related to GRP, but its role in itch is unclear.

275 toradiography, Lu-AMBA binds specifically to GRP-R (0.8 nmol/L) and to the neuromedin B receptor (NMB

276 ities (IC(50)) of AuNP-BBN conjugates toward GRP receptors on human prostate cancer cells have been i

277 In addition, transient GRP blockade could mitigate PF in normal lung after ther

278 We transplanted GRPs around cervical spinal cord respiratory motor neuro

279 with wild-type littermates, bombesin-treated GRP receptor (GRPR)-null mice had increased interstitial

280 est whether radiation (RT) exposure triggers GRP release in mice and whether this contributes to RTPF

281 ypothesized that ionizing radiation triggers GRP secretion, contributing to inflammatory and fibrotic

282 release of the EGFR ligand amphiregulin upon GRP treatment.

283 d kinase to directly phosphorylate TACE upon GRP treatment.

284 Urine GRP levels were significantly elevated between 24 hours

285 2A11, given minutes post-RT, abrogated urine GRP levels by 6 to 12 hours and also altered phosphoprot

286 We determined urine GRP levels and lung GRP immunostaining in mice 0 to 24 a

287 Therefore, elevation of urine GRP could be predictive of RTPF development.

288 Titration of the most commonly used GRP antiserum in tissues from wild-type and GRP mutant m

289 Targeting GRP-R-expressing BC tumors using GRP-R radioligands is promising for nuclear imaging and

290 peptidergic cells of the SCN, including VIP, GRP, and arginine vasopressin (AVP) neurons, with each i

291 In vitro GRP application resulted in persistent increases in the

292 In vitro, GRP-induced neutrophil migration was dependent on PLC-be

293 When GRPs were transplanted into either normal spinal cord of

294 ernalization of both GRPR and MOR1D, whereas GRP specifically triggers GRPR internalization and morph

295 cellular levels, and we also tested whether GRP actions are dependent on activation of the cAMP resp

296 ransferrin, the protein was derivatized with GRP and trypsin digested.

297 Therefore, binding of DMP1 with GRP-78 receptor might be an important mechanism by which

298 Co-localization of DMP1 with GRP-78 was also observed in T4-4 preodontoblast cells, d

299 combined immunodeficient mice implanted with GRP-autocrine LNCaP cells.

300 Incubation of myometrium with GRP receptor antagonists attenuates the effect of stretc